Literature DB >> 12193459

Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure.

Margaret P Chandler1, William C Stanley, Hideaki Morita, George Suzuki, Bridgette A Roth, Brent Blackburn, Andrew Wolff, Hani N Sabbah.   

Abstract

The present study assesses whether ranolazine increases left ventricular (LV) function without an increase in myocardial oxygen consumption (MVO2) and thus improves LV mechanical efficiency in dogs with heart failure (HF). Ranolazine did not change MVO2 and LV mechanical efficiency increased (22.4+/-2.8% to 30.9+/-3.4% (P<0.05). In contrast, dobutamine significantly increased MVO2 and did not improve mechanical efficiency. Thus, short-term treatment with ranolazine improved LV function without an increase in MO2, resulting in an increased myocardial mechanical efficiency in dogs with HF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193459     DOI: 10.1161/01.res.0000031151.21145.59

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  35 in total

Review 1.  Ranolazine: a review of its use in chronic stable angina pectoris.

Authors:  M Asif A Siddiqui; Susan J Keam
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Excitation-contraction coupling and mitochondrial energetics.

Authors:  Christoph Maack; Brian O'Rourke
Journal:  Basic Res Cardiol       Date:  2007-07-27       Impact factor: 17.165

Review 3.  Modulating fatty acid oxidation in heart failure.

Authors:  Vincenzo Lionetti; William C Stanley; Fabio A Recchia
Journal:  Cardiovasc Res       Date:  2011-02-02       Impact factor: 10.787

Review 4.  Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

Review 5.  Mitochondria as a drug target in ischemic heart disease and cardiomyopathy.

Authors:  Andrew M Walters; George A Porter; Paul S Brookes
Journal:  Circ Res       Date:  2012-10-12       Impact factor: 17.367

6.  Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.

Authors:  Sharad Rastogi; Victor G Sharov; Sudhish Mishra; Ramesh C Gupta; Brent Blackburn; Luiz Belardinelli; William C Stanley; Hani N Sabbah
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-09-26       Impact factor: 4.733

7.  Assessment of metabolic phenotypes in patients with non-ischemic dilated cardiomyopathy undergoing cardiac resynchronization therapy.

Authors:  Sebastian Obrzut; Jay Tiongson; Neema Jamshidi; Huy Minh Phan; Carl Hoh; Ulrika Birgersdotter-Green
Journal:  J Cardiovasc Transl Res       Date:  2010-09-15       Impact factor: 4.132

8.  Emerging clinical role of ranolazine in the management of angina.

Authors:  David S Vadnais; Nanette K Wenger
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

9.  Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.

Authors:  Gernot Schram; Liming Zhang; Katayoun Derakhchan; Joachim R Ehrlich; Luiz Belardinelli; Stanley Nattel
Journal:  Br J Pharmacol       Date:  2004-07-26       Impact factor: 8.739

10.  Mechanism of reduced myocardial glucose utilization during acute hypertriglyceridemia in rats.

Authors:  Sébastien L Ménard; Xiuli Ci; Frédérique Frisch; François Normand-Lauzière; Jules Cadorette; René Ouellet; Johannes E Van Lier; François Bénard; M'hamed Bentourkia; Roger Lecomte; André C Carpentier
Journal:  Mol Imaging Biol       Date:  2008-09-04       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.